Two hands gently holding each other against a dark background, symbolic image for Alzheimer's care and research

Alzheimer’s Pill AR1001: A Viagra Cousin Slowed Decline by 31 Percent, but Only in Some Patients

Editorial Team

Pharmaceutical history is full of happy accidents. Viagra famously started out in heart research before scientists noticed a rather different effect. Now a pill from the same drug family is trying to pull the trick in reverse: a compound first developed for erectile dysfunction has been tested as a treatment for Alzheimer’s disease. On Monday, November 16, the results of a large Phase 3 trial were presented in Boston. The headline sounds spectacular. The details are where it gets interesting. You deserve both.

What the POLARIS-AD trial tested

The drug is called AR1001, developed by the South Korean company AriBio. It is a PDE5 inhibitor, the same class of medicine as Viagra, designed to cross the blood-brain barrier. According to the Washington Post, as summarized by Newser, the compound is sold in South Korea as an erectile dysfunction pill under the name Mvix. In the Alzheimer’s trial it was given as a once-daily 30 milligram tablet.

The study, called POLARIS-AD, enrolled 1,535 people with early Alzheimer’s disease at around 230 sites in 13 countries, including the United States, the UK, several EU member states, South Korea, China and Canada. Participants took either AR1001 or a placebo every day for 52 weeks. Global principal investigator Sharon J. Sha presented the results at the Clinical Trials on Alzheimer’s Disease conference (CTAD).

The main yardstick was the CDR-SB, a standard clinical scale that rates memory, orientation, judgment, community affairs, home life and personal care. The researchers analyzed it in two prespecified groups: everyone in the trial plus a “monotherapy” group of 604 people who were not taking the established symptom-relieving dementia drugs (acetylcholinesterase inhibitors or memantine) at the start.

The result: a clear yes for some, a shrug for the whole

In the monotherapy group, AR1001 slowed decline on the CDR-SB by 0.44 points compared with placebo after one year. AriBio describes that as a 31 percent slowing of clinical decline, which the Washington Post translated into a delay of a little more than three months. The result was statistically significant. A second cognitive test, the MMSE, also favored the drug in that group.

In the full trial population, however, the difference was just 0.11 points and not statistically significant. Put simply: in roughly 60 percent of participants, those already on standard dementia medication, the pill showed little or no extra benefit. Nobody yet knows why. One possibility researchers will have to explore is that the existing drugs and AR1001 overlap in some way, but that is an open question rather than a finding.

Biomarkers offer a few clues. Levels of cGMP in spinal fluid rose in both groups, which the company says shows the drug reached its target in the brain. In the monotherapy group, p-tau217, a marker linked to the tau tangles of Alzheimer’s, was modestly lower than with placebo. Amyloid, the protein targeted by the antibody infusions approved in recent years, did not change.

Safety: mostly unremarkable, with some caveats

Serious adverse events occurred in 10.0 percent of people on AR1001 and 9.8 percent on placebo. The most common side effects were diarrhea (7.7 versus 4.4 percent), falls (7.3 versus 5.9 percent) and dizziness (6.1 versus 3.1 percent). More people stopped the drug because of side effects (5.2 versus 1.7 percent). Four deaths were recorded in the AR1001 group and two in the placebo group; the company’s release does not attribute them to the drug.

Falls and dizziness matter in an older population, so regulators will look at those numbers closely. Researchers have also stressed that AR1001 is not the same as Viagra, since its formulation and dose differ. Your medicine cabinet is not secretly a memory clinic. Nobody should start experimenting on their own.

How excited should you be?

Independent experts are cautiously interested. Neuroscientist Atticus Hainsworth of City St George’s, University of London, told the Washington Post it was “early days to say much definitively,” while adding that the evidence “looks pretty good to me.” Outside experts consistently describe the findings as preliminary.

The appeal is obvious. Today’s antibody treatments are infusions that require regular clinic visits. A daily pill taken at home would be a very different proposition for patients and families. Repurposed drugs also come with years of safety experience in other uses. Earlier research had already hinted that PDE5 inhibitors might have something to do with brain health.

The hurdle is equally obvious. Regulators have historically wanted a drug to succeed across the whole trial population, not only in one subgroup. AriBio says it will discuss the full data with the US Food and Drug Administration and present further analyses. A 52-week open-label extension, in which all participants receive AR1001, is expected to finish in the third quarter of 2027. The company itself states that AR1001 is investigational and has not been approved by any regulator for Alzheimer’s.

The bigger picture

Alzheimer’s research has spent decades chasing amyloid, with mixed rewards. A drug that works through a completely different mechanism, at least in some patients, is scientifically valuable even if it never reaches a pharmacy. If AR1001 does get there one day, it will be a classic repurposing story. If it does not, it will still have taught researchers something about who benefits and why. Either way, the honest headline reads something like “an old idea earned a closer look,” which is less catchy than “Viagra cures Alzheimer’s” and considerably more accurate.

This article is for general information only and does not replace professional medical advice. If you have questions about memory problems or dementia treatment, please talk to your doctor.

Key facts at a glance

  • What: AR1001, an oral PDE5 inhibitor from AriBio, was tested in the Phase 3 POLARIS-AD trial in early Alzheimer’s disease.
  • Who: The trial enrolled 1,535 people at about 230 sites in 13 countries for 52 weeks.
  • Result: In 604 people not taking other dementia drugs, AR1001 slowed decline on the CDR-SB by 0.44 points, a 31 percent slowing; the overall population showed no significant benefit.
  • When: Results were presented at the CTAD conference in Boston on November 16, 2026.
  • Status: AR1001 is not approved for Alzheimer’s; AriBio plans to discuss the data with the FDA.
  • Note: for general information only, not medical advice.

FAQ

Does the erectile dysfunction drug AR1001 slow Alzheimer’s?
In the POLARIS-AD trial it slowed decline by 31 percent in people not taking other dementia drugs. In the full trial population the effect was not statistically significant.

Is AR1001 the same as Viagra?
No. AR1001 belongs to the same drug class as Viagra but is a different compound with a different formulation and dose.

When could AR1001 be approved for Alzheimer’s disease?
No approval timeline exists. AriBio plans to discuss the data with the FDA. An open-label extension is expected to end in the third quarter of 2027.

This article was created with AI assistance and is based on the sources listed.